Cas:23056-94-2 2-methylhex-1-en-3-yne manufacturer & supplier

We serve Chemical Name:2-methylhex-1-en-3-yne CAS:23056-94-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-methylhex-1-en-3-yne

Chemical Name:2-methylhex-1-en-3-yne
CAS.NO:23056-94-2
Synonyms:1-Hexen-3-yne,2-methyl;2-Methyl-1-hexen-3-yne;2-methyl-hex-1-en-3-yne;MFCD00041629;2-methylhexen-3-yne
Molecular Formula:C7H10
Molecular Weight:94.15430
HS Code:2901299090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:103ºC
Density:0.75
Index of Refraction:n20/D 1.45(lit.)
PSA:
Exact Mass:94.07830
LogP:1.97590

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3295 3/PG 1
Packing Group:II


Contact us for information like 1-Hexen-3-yne,2-methyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methylhexen-3-yne physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-hex-1-en-3-yne Use and application,2-methylhexen-3-yne technical grade,usp/ep/jp grade.


Related News: Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 2-methylhex-1-en-3-yne manufacturer In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 2-methylhex-1-en-3-yne supplier Pharmaceutical intermediates and APIs belong to the fine chemical industry. 2-methylhex-1-en-3-yne vendor In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC. 2-methylhex-1-en-3-yne factory Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.